Horizon Pharma (HZNP) PT Raised to $39 at Cowen

November 6, 2019 10:05 AM EST
Get Alerts HZNP Hot Sheet
Price: $116.45 -0.01%

Rating Summary:
    15 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 18 | New: 32
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cowen analyst Ken Cacciatore raised the price target on Horizon Pharma (NASDAQ: HZNP) to $39.00 (from $35.00) while maintaining a Outperform rating.

The analyst commented, "Horizon's Q3 was nicely above, with the key outperformance all due to the more durable orphan portfolio, which now comprises 75% of total revenue. The primary driver was Krystexxa, which was up +42% Y/Y, and has clearly established itself as the backbone growth asset in the P&L. With Tepro set to provide meaningful P&L leverage & duration, the growth story is set to even further accelerate. Add."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cowen & Co